Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — Q1 2023 Earnings Presentation
157 slides from Novo Nordisk A/s Class B's earnings presentation, May 4, 2023
Slide 1: Novo Nordisk – a focused healthcare company
1 Investor presentation First three months of 2023 Novo Nordisk –a focused healthcare company Investor presentation First three months of 2023 Erik Hageman (on the right) is one of Denmark’s longest-living people with type 1 diabetes, pictured here with his son Lars, who also has type 1 diabetes, an
Slide 2: Agenda
2 Investor presentation First three months of 2023 Novo Nordisk® Progress on Strategic Aspirations 2025 Agenda Agenda Commercial execution Innovation and therapeutic focus Financials
Slide 3: Forward-looking statements
3 Investor presentation First three months of 2023 Novo Nordisk® Forward-looking statements Novo Nordisk’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the statutory Annual Report 2022 and Form 20-F, which both were filed with the SEC in February 2023
Slide 4: Strategic Aspirations 2025 – Highlights first three months 2023
4 Investor presentation First three months of 2023 Novo Nordisk® Strategic Aspirations 2025 | Highlights first three months 2023 Progress towards zero environmental impact Further raise innovation bar for Diabetes treatment • Regulatory submission of once-weekly insulin icodec • Carbon emissions dec
Slide 5: Sales growth of 25% driven by both operating units
5 Investor presentation First three months of 2023 Novo Nordisk® Sales growth of 25% driven by both operating units Reported geographic sales split for first quarter of 2023 Reported therapy area sales and growth for first quarter of 2023 DKK Insulin GLP-1 Other diabetes DKK North America Operations
Slide 6: Diabetes value market leadership increased by 1.7%-points to 32.2%
6 Investor presentation First three months of 2023 Novo Nordisk® Diabetes value market leadership increased by 1.7%-points to 32.2% Novo Nordisk global diabetes value market shares Diabetes value market leadership expansion driven by the GLP-1 franchise 60% Diabetes GLP-1 Insulin 54.4% Diabetes care
Slide 7: International Operations diabetes care sales growth is driven by GLP-1 performance
7 Investor presentation First three months of 2023 Novo Nordisk® International Operations diabetes care sales growth is driven by GLP-1 performance Reported Diabetes care sales and growth per IO geography GLP-1 patients and value market share in IO DKK Number of Value billion Insulin GLP-1 Growth at
Slide 8: GLP-1 class expansion accelerates in the US in the first quarter of 2023
8 Investor presentation First three months of 2023 Novo Nordisk® GLP-1 class expansion accelerates in the US in the first quarter of 2023 with volume growth across our portfolio US GLP-1 weekly NBRx prescriptions US GLP-1 TRx market share Weekly NBRx Total GLP-1 scripts TRx share scripts (‘000s) (mi
Slide 9: Obesity care sales grew by 124% in the first quarter of 2023
9 Investor presentation First three months of 2023 Novo Nordisk® Obesity care sales grew by 124% in the first quarter of 2023 mainly driven by the US following relaunch of Wegovy NN sales and volume BAOM market growth Branded AOM TRx in the US2 within Obesity care DKK billion TRx count (‘000s) 10 14
Slide 10: Rare disease sales decreased by 16% driven by temporary reduction in manufacturing output
10 Investor presentation First three months of 2023 Novo Nordisk® Rare disease sales decreased by 16% driven by temporary reduction in manufacturing output Reported Rare disease sales Rare disease sales driven by global commercial execution DKK billion Growth at CER Rare disease sales decrease is dr
Slide 11: PIONEER PLUS achieved its primary endpoint vs oral sema 14 mg
11 Investor presentation First three months of 2023 Novo Nordisk® PIONEER PLUS achieved its primary endpoint and demonstrated statistically significant HbA1C reduction vs oral sema 14 mg Oral semaglutide 25 mg and 50 mg vs 14 mg in subjects with T2D Headline trial results Change in HbA1C Change in b
Slide 12: R&D milestones
12 Investor presentation First three months of 2023 Novo Nordisk® R&D milestones Clinical milestones1 Regulatory milestones1 Project Q1 2023 Q2 2023 H2 2023 Diabetes care Insulin Icodec ✓ EU/US/CN submission Oral semaglutide (25/50mg) ✓ Phase 3 results US submission FDC semaglutide/GIP OW ✓ Phase 2
Slide 13: Financial results – First three months of 2023
13 Investor presentation First three months of 2023 Novo Nordisk® Financial results – First three months of 2023 First three First three Change Change In DKK million months of 2023 months of 2022 (reported) (CER) Sales 53,367 42,031 27% 25% Gross profit 45,185 35,114 29% 26% Gross margin 84.7% 83.5%
Slide 14: Financial outlook for 2023
14 Investor presentation First three months of 2023 Novo Nordisk® Financial outlook for 2023 Expectations Expectations 4 May 2023 1 Feb 2023 Sales growth – at CER 24% to 30% 13% to 19% Sales growth - reported Around 6 percentage points lower Around 4 percentage points lower Operating profit growth –
Slide 15: Strategic aspirations 2025
15 Investor presentation First three months of 2023 Novo Nordisk® Strategic aspirations 2025 • Further raise the innovation-bar for diabetes treatment therapeutic focus • Progress towards zero environmental impact • Develop a leading portfolio of superior treatment Innovation and solutions for obesi
Slide 16: Investor contact information
16 Investor presentation First three months of 2023 Novo Nordisk® Investor contact information Share information Investor Relations contacts Novo Nordisk’s B shares are listed on the stock exchange in Copenhagen Novo Nordisk A/S under the symbol ‘NOVO B’. Its ADRs are listed on the New York Stock In
Slide 17: Appendix
17 Investor presentation First three months of 2023 Novo Nordisk® Novo Nordisk corporate strategy 18 Diabetes care 31 GLP-1 40 Insulin 46 Appendix Obesity care 51 Rare disease 70 Other serious chronic diseases 83 Regional information 101 Financials 133 Sustainability 143
Slide 18: Novo Nordisk Corporate Strategy
18 Investor presentation First three months of 2023 Novo Nordisk® Novo Nordisk Corporate Strategy Rare disease
Slide 19: Large unmet needs across all therapy areas in scope
19 Investor presentation First three months of 2023 Novo Nordisk® Novo Nordisk’s opportunity is in the large unmet needs across all therapy areas in scope Diabetes care Obesity care 537m people with ~15% >764m people with ~2% of people in of people in medically diabetes1 good control2 obesity3 treat
Slide 20: Leading positions in diabetes, obesity and haemophilia
20 Investor presentation First three months of 2023 Novo Nordisk® Novo Nordisk has leading positions in diabetes, obesity and haemophilia Diabetes care Obesity care Haemophilia DKK DKK DKK billion billion billion 1000 #1 50% 40 #1 100% 100 #3 50% 800 40% 80% 80 40% 30 600 30% 60% 60 30% 20 400 20% 4
Slide 21: Sales growth of 25%, driven by the GLP-1 portfolio
21 Investor presentation First three months of 2023 Novo Nordisk® Sales growth of 25%, driven by the GLP-1 portfolio for diabetes and obesity treatment Novo Nordisk reported quarterly sales Reported sales for the first Reported sales and growth breakdown for DKK by therapy quarter of 2023 the first
Slide 22: Sales growth driven by both NAO and IO
22 Investor presentation First three months of 2023 Novo Nordisk® Sales growth of 25%, driven by both NAO and IO with 41% and 10% sales growth respectively Historic and reported sales by geography Reported sales and growth breakdown for the first quarter of 2023 Total in DKK billion 111.8 177.0 53.4
Slide 23: Solid patent protection, high barriers to entry, collaborative innovation
23 Investor presentation First three months of 2023 Novo Nordisk® Novo Nordisk holds solid patent protection, high barriers to entry, and a collaborative approach to innovation Novo Nordisk’s position is protected Barriers to entry for biosimilar players Partnerships and acquisitions support by pate
Slide 24: Dicerna acquisition and RNAi technology
24 Investor presentation First three months of 2023 Novo Nordisk® The acquisition of Dicerna Pharmaceuticals and their RNAi technology in 2021 provided access to intracellular targets Disease targets (expressed genes) Peptides and proteins ~5,000 extracellular targets Cell Engage on the RNAi tempora
Slide 25: First two human dose initiations with Dicerna
25 Investor presentation First three months of 2023 Novo Nordisk® First two human dose initiations with Dicerna in line with ambition presented at Capital Markets Day 2022 First two phase 1 trials in NASH with siRNA technology initiated Novo Nordisk and Dicerna • After a productive partnership since
Slide 26: Core capabilities provide a competitive advantage
26 Investor presentation First three months of 2023 Novo Nordisk® Novo Nordisk’s core capabilities provide a competitive advantage to continue to defeat diabetes Engineering, formulating, Efficient large-scale Global commercial reach and Deep disease developing and delivering production of proteins
Slide 27: Technology platforms across therapy areas
27 Investor presentation First three months of 2023 Novo Nordisk® Core capabilities and additional technology platforms open up new opportunities across therapy areas Technology platforms Proteins / Peptides Oligonucleotides / RNAi Stem cells Genome editing / Gene therapy Diabetes care Obesity care
Slide 28: Human data-driven decision-making with faster timelines
28 Investor presentation First three months of 2023 Novo Nordisk® Human data-driven decision-making with faster timelines to enable a robust development pipeline Speed up time to reach FHD and increase number of phase 1 assets Future Research & early development trends for Novo Nordisk ILLUSTRATIVE
Slide 29: Pipeline supports growth across four strategic focus areas
29 Investor presentation First three months of 2023 Novo Nordisk® Pipeline supports significant growth opportunities across all four strategic focus areas PHASE 1 PHASE 2 PHASE 3 SUBMITTED APPROVED NN1845 – GSI NN9388 – Cagrisema NN1535 – Icosema NN1436 – Insulin Icodec Tresiba® NN1471 – Pumpinsulin
Slide 30: Global manufacturing setup
30 Investor presentation First three months of 2023 Novo Nordisk® Novo Nordisk has a global manufacturing setup Local production All products API, fill and finish Russia API, fill and finish Fill and finish Japan Iran Algeria Fill and finish Fill and finish Product Supply value chain Research and Ma
Slide 31: Diabetes care
31 Investor presentation First three months of 2023 Diabetes care Disease and market 32 GLP-1 segment 40 Insulin segment 46 SIMONE LENSBØLE Simone lives with type 2 diabetes Denmark
Slide 32: Diabetes – the inability to manage blood sugar levels
32 Investor presentation First three months of 2023 Novo Nordisk® Diabetes – the inability to manage blood sugar levels appropriately Facts about diabetes Insulin analogue action profiles Diabetes is a chronic disease that occurs either when the pancreas does not produce enough insulin or when the b
Slide 33: GLP-1s have positive effects beyond glycaemic control
33 Investor presentation First three months of 2023 Novo Nordisk® GLP-1s have positive effects beyond glycaemic control and treatment guidelines now reflect the CV risk benefits Medications for treatment of type 2 diabetes Updated ADA/EASD diabetes treatment guidelines Hypo Weight Cardiovascular eff
Slide 34: Increased mortality risk and growing diabetic population
34 Investor presentation First three months of 2023 Novo Nordisk® People with diabetes have increased mortality risk, and the diabetic population is expected to increase to 784 million by 2045 Diabetes is associated with shorter life expectancy The number of people with diabetes is expected to and l
Slide 35: Unmet need within diabetes care remains large
35 Investor presentation First three months of 2023 Novo Nordisk® The unmet need within diabetes care remains large with too few patients reaching glycaemic target and treated for complications 1 in 2 adults go undiagnosed and more treated patients Of the 537 million, 36.3 million1 people are curren
Slide 36: Diabetes requires treatment intensification over time
36 Investor presentation First three months of 2023 Novo Nordisk® Diabetes is a chronic disease requiring treatment intensification over time Distribution of estimated prescriptions1 and value across treatment classes Diet and exercise 3% OAD 12% -cell function 51% 21% GLP-1 3% 34% Insulin 13% 12%
Slide 37: Continued innovation supported by digital solutions
37 Investor presentation First three months of 2023 Novo Nordisk® Better outcomes and broader reach can be accomplished through continued innovation, supported by digital solutions Novo Nordisk’s product portfolio follows the patient treatment journey • Innovation focused on oral GLP-1 Portfolio and
Slide 38: Total branded diabetes market ~DKK 380 billion
38 Investor presentation First three months of 2023 Novo Nordisk® The total branded diabetes market has a global value of DKK ~380 billion annually DKK Global diabetes market DKK The USA billion +13% billion +13% 400 382 187 2022 2021 Growth at CER 200 147 +27% 150 314 -17% -11% 98 100 68 +42% 300 -
Slide 39: Leadership position within the growing diabetes market
39 Investor presentation First three months of 2023 Novo Nordisk® Novo Nordisk has a leadership position within the growing diabetes market Global diabetes market by treatment class1 Novo Nordisk remains global diabetes value Novo Nordisk market share and share of market leader growth DKK billion Ma
Slide 40: GLP-1 effect dependent on blood glucose level
40 Investor presentation First three months of 2023 Novo Nordisk® GLP-1 effect dependent on blood glucose level GLP-1 mechanism of action when blood Semaglutide holds a plethora of therapeutic opportunities1 sugar levels increase Diabetes FOCUS - Diabetic retinopathy outcomes trial Creates sense of
Slide 41: 54% of the global GLP-1 market
41 Investor presentation First three months of 2023 Novo Nordisk® Novo Nordisk has 54% of the global GLP-1 market, while GLP-1 penetration of diabetes volume varies across regions GLP-1 market growth and Novo Nordisk market share GLP-1 share of total estimated diabetes prescriptions1 is 5% Million p
Slide 42: SUSTAIN trials with subcutaneous semaglutide
42 Investor presentation First three months of 2023 Novo Nordisk® SUSTAIN trials with subcutaneous semaglutide SUSTAIN 1 2 3 4 5 6 7 Baseline 8.1% 8.1% 8.3% 8.2% 8.4% 8.7% 8.2% -0.1 -0.4 Change in -0.5 HbA1c (%) -0.8 -0.9 -1.1 * -1.1 * -1.2 * * -1.3 * -1.3 * * -1.4 * -1.4 * * * -1.5 * -1.5 * * -1.8
Slide 43: PIONEER programme with oral semaglutide
43 Investor presentation First three months of 2023 Novo Nordisk® PIONEER programme with oral semaglutide PIONEER 1 2 3 4 5 7 8 Baseline 8.0% 8.1% 8.3% 8.0% 8.0% 8.3% 8.2% -0.1 -0.1 -0.1 Change in -0.5 -0.6 * HbA1c (%) -0.7 -0.8 * -0.8 * * -1.0 -0.9 -1.1 -1.1 * -1.1 -1.3 * * -1.4 * -1.4 * -1.3 * -1.
Slide 44: Semaglutide 2.0 mg s.c. SUSTAIN FORTE
44 Investor presentation First three months of 2023 Novo Nordisk® Semaglutide 2.0 mg s.c. brings patients needing treatment intensification to target Phase 3 trial, SUSTAIN FORTE, completed and label application Data from SUSTAIN FORTE approved in the US and the EU Semaglutide 2.0 mg showed superior
Slide 45: Phase 2 trial for CagriSema in type 2 diabetes
45 Investor presentation First three months of 2023 Novo Nordisk® Phase 2 trial for CagriSema in people with type 2 diabetes was successfully completed in Q3 2022 Exploratory phase 2a trial of CagriSema in T2D Headline trial results Cagrilintide 2.4 mg + semaglutide 2.4 mg Change in HbA1C Change in
Slide 46: Global insulin market leadership at 46.3%
46 Investor presentation First three months of 2023 Novo Nordisk® Novo Nordisk global insulin market leadership at 46.3% and the global insulin volume market declined by 1.3% North America Operations Global International Operations Market growth: -1.3% Market growth: -0.6% Market growth: -3.4% MS 46
Slide 47: Insulin market size and volume share
47 Investor presentation First three months of 2023 Novo Nordisk® Insulin market size and volume share of growth and market share Insulin market share and market size (DKK billion) Market Δ Market Insulin volume: Market share growth share Total 45% 274 3.4% +0.5% 50% 46% 10% 40% 7% Long- 2.9% +1.3%
Slide 48: Insulin icodec once-weekly basal insulin
48 Investor presentation First three months of 2023 Novo Nordisk® Insulin icodec, a basal insulin intended for once-weekly treatment, may reduce the disease burden for patients Bringing the strongest value Insulin icodec phase 3 programme completed in 2022 proposition to market Reduction of disease
Slide 49: ONWARDS programme with insulin icodec
49 Investor presentation First three months of 2023 Novo Nordisk® The full ONWARDS programme with once-weekly insulin Icodec completed in 2022 ONWARDS 1 2 3 4 5 6 Basal initiation Basal switch Basal initiation Basal/Bolus Basal initiation Basal/Bolus Duration 52 weeks2 26 weeks 26 weeks 26 weeks 52
Slide 50: Phase 3 programme COMBINE with IcoSema
50 Investor presentation First three months of 2023 Novo Nordisk® Phase 3 trial programme, COMBINE, has been initiated with IcoSema IcoSema characteristics Focused phase 3 trial programme COMBINE 1 • Initiated in Q2 2022 Post-basal insulin • 1290 patients* previously on basal-insulin IcoSema is a fi
Slide 51: Obesity care
51 51 Investor presentation First three months of 2023 Novo Nordisk® Obesity care Obesity disease background 58 52 Obesity market development 62 56 Innovation 63 57 MICHAEL PETERSEN Michael lives with obesity Denmark
Slide 52: More than 764 million people living with obesity
52 Investor presentation First three months of 2023 Novo Nordisk® More than 764 million people are living with obesity, yet the narrative is changing Obesity is a global epidemic Obesity impacts both the individual and The obesity narrative is changing affecting more than 764 million people1 society
Slide 53: Patient-centric strategy for obesity
53 Investor presentation First three months of 2023 Novo Nordisk® Patient-centric strategy designed to activate more people with obesity, drive HCP engagement, and improve market access Million people >764 million people live with obesity 800 ~10% seek help ~2% are treated with an AOM ~2.5 million s
Slide 54: Large opportunity for activating more people with obesity
54 Investor presentation First three months of 2023 Novo Nordisk® Large opportunity for activating more people with obesity to seek treatment and increasing the number of prescribers Wegovy® patient characteristics in the US 70% 81% 37.8 31% of patients new to anti- of patients are female Average BM
Slide 55: Patient access to anti-obesity medications is improving
55 Investor presentation First three months of 2023 Novo Nordisk® Patient access to anti-obesity medications is improving in both the US and IO The >40 million people having access to Wegovy® is nearly the number Restricted reimbursement for Saxenda® is progressing of people with diabetes in the US
Slide 56: Global obesity market growth accelerating
56 Investor presentation First three months of 2023 Novo Nordisk® Global obesity market growth has been accelerating with Novo Nordisk capturing the majority of growth Obesity market growth and Novo Nordisk value market share Obesity market size and growth DKK billion ~78% 180% 180% 29.7 0.2 140% 14
Slide 57: STEP trials weight loss with semaglutide 2.4 mg
57 Investor presentation First three months of 2023 Novo Nordisk® Across the STEP 1, 3, and 4 trials, a weight loss of 16.9% to 18.2% was reported for people treated with semaglutide 2.4 mg STEP 1 STEP 3 STEP 4 STEP 5 STEP 2 STEP 8 Weight Weight mgmt. Sustained weight management Weight loss over 2 W
Slide 58: STEP 1 weight loss up to 16.9%
58 Investor presentation First three months of 2023 Novo Nordisk® In STEP 1, people treated with semaglutide had a superior weight loss of up to 16.9% The pivotal STEP 1 trial showed greater than 16% weight loss Data from STEP 1 % change in body weight 0 • Average age 46 Placebo: -2.4% • 74.1% women
Slide 59: STEP 1 categorical weight loss and quality of life
59 Investor presentation First three months of 2023 Novo Nordisk® In STEP 1, 34.8% of patients treated with sema reached ≥20% weight loss and reported improved quality of life versus placebo Categorical weight loss Semaglutide 2.4 mg showed a statistically significant treatment difference versus pla
Slide 60: STEP 4 weight loss up to 18.2%
60 Investor presentation First three months of 2023 Novo Nordisk® In STEP 4, people treated with semaglutide had a superior weight loss of up to 18.2% STEP 4 showed significantly greater weight loss post run-in than placebo Data from STEP 4 % change in body weight Randomisation 0 • Average age 46 •
Slide 61: STEP 4 categorical weight loss and quality of life
61 Investor presentation First three months of 2023 Novo Nordisk® In STEP 4, 41.2% of patients treated with semaglutide reached ≥20% weight loss and reported improved quality of life vs placebo Categorical weight loss Semaglutide 2.4 mg showed a statistically significant treatment difference versus
Slide 62: STEP 5 sustained weight loss over 2 years
62 Investor presentation First three months of 2023 Novo Nordisk® In STEP 5, people treated with semaglutide 2.4 mg sustained their weight loss over 2 years Clinically relevant and sustained weight loss in patients Data from STEP 5 with obesity or overweight % change in body weight Placebo: -0.6% 40
Slide 63: STEP 8 semaglutide vs liraglutide
63 Investor presentation First three months of 2023 Novo Nordisk® In STEP 8, semaglutide 2.4 mg showed weight loss of 17.1% compared to 6.6% with liraglutide 3.0 mg Data from STEP 8 STEP 8 observed mean change in body weight1 Mean baseline body weight: 104.5 kg 0 38.5% of patients lost ≥20% of their
Slide 64: OASIS trial oral semaglutide 50 mg in obesity
64 Investor presentation First three months of 2023 Novo Nordisk® The phase 3a OASIS trial investigating oral semaglutide 50 mg in obesity initiated in Q3 2021 and expected to complete in H1 2023 Global trial planned was started in H2 2021 Plan to include 660 patients with obesity Objective To inves
Slide 65: CagriSema 20-week phase 1 weight loss
65 Investor presentation First three months of 2023 Novo Nordisk® In a 20-week phase 1 trial, CagriSema showed weight loss of 17% and appeared to have a safe and well tolerated profile Weight loss for different doses of CagriSema in phase 1 The GI profile appeared similar to semaglutide 2.4 monother
Slide 66: CagriSema REDEFINE phase 3 programme
66 Investor presentation First three months of 2023 Novo Nordisk® The CagriSema phase 3 programme, REDEFINE, was initiated in the fourth quarter of 2022 REDEFINE 1 trial design REDEFINE 2 trial design CagriSema 2.4 mg/2.4 mg1 N = 3400 N=1200 Cagrilintide 2.4 mg1 CagriSema 2.4 mg/2.4 mg1 R R Semaglut
Slide 67: SELECT cardiovascular outcomes trial
67 Investor presentation First three months of 2023 Novo Nordisk® The SELECT cardiovascular outcomes trial expected to complete in the middle of 2023 Objective Demonstrate that semaglutide s.c. 2.4 mg OW lowers the incidence MACE vs. placebo when both added to standard of care in subjects with estab
Slide 68: SELECT addresses comorbidities improved by weight management
68 Investor presentation First three months of 2023 Novo Nordisk® The cardiovascular trial, SELECT, addresses many comorbidities that can be improved with weight management Improvements per weight loss bracket Weight loss (%) 30 >15% 20 10-15% 5-10% 10 0-5% 0 Hypertension X Dislipidaemia X Kidney di
Slide 69: Oral amycretin phase 1
69 Investor presentation First three months of 2023 Novo Nordisk® Oral amycretin entered phase 1 in Q2 2022, combining protein and peptide expertise with oral technology Amycretin is a GLP-1 and amylin receptor Phase 1 single dose and multiple dose trial for co-agonist intended for oral delivery ora
Slide 70: Rare disease
70 70 Investor presentation First three months of 2023 Novo Nordisk® Rare disease Rare Raredisease diseasebackground background 76 71 Rare Raredisease diseaseinnovation innovation 79 74 SIERRA CLARK Sierra lives with Glanzmann-Thrombasthenia Canada
Slide 71: Building on a 40-year legacy in Rare disease
71 Investor presentation First three months of 2023 Novo Nordisk® Building upon a 40-year legacy to capture the Rare disease strategic opportunity A strategy anchored in Rare blood and endocrine disorders Three strategic horizons towards 2030 Hemato-renal Lysosomal storage disorders Long-term Haemog
Slide 72: Rare disease sales decreased by 16%
72 Investor presentation First three months of 2023 Novo Nordisk® Rare disease sales decreased by 16%, driven by driven by temporary reduction in manufacturing output NovoSeven® and Norditropin® Global Rare disease franchise DKK account for ~70% of Rare disease sales DKK billion billion 25 25 1% 4%
Slide 73: Haemophilia unmet need but competitive market
73 Investor presentation First three months of 2023 Novo Nordisk® Haemophilia is a rare disease with severe unmet medical needs but the market is highly competitive Recombinant haemophilia product sales DKK billion 50 +15% 40 30 20 -0.1% +31% 10 0 2018 2022 2018 2022 2018 2022 Haemophilia with inhib
Slide 74: Explorer 7 trial of concizumab
74 Investor presentation First three months of 2023 Novo Nordisk® Explorer 7 trial evaluated safety and efficacy of concizumab in 132 haemophilia A and B patients with inhibitors Concizumab binds TFPI, enabling Explorer 7 trial design thrombin generation and clot formation Concizumab 1) Maintained O
Slide 75: Concizumab reduced bleeds in patients with inhibitors
75 Investor presentation First three months of 2023 Novo Nordisk® In the Explorer 7 trial, concizumab reduced the number of bleeds in adults and adolescents with inhibitors Explorer 7 trial results: Annualised bleeding rate per patient group Key highlights Efficacy 100 Median Mean • Median ABR was 0
Slide 76: explorer8 trial completed main part
76 Investor presentation First three months of 2023 Novo Nordisk® Main part of the explorer8 trial with concizumab in people with HA or HB without inhibitors has been completed explorer8 trial design Key trial highlights 1 Maintained OnD treatment Efficacy Previously OnD treatment R • The trial met
Slide 77: Mim8 phase 1/2 PK/PD profile
77 Investor presentation First three months of 2023 Novo Nordisk® Interim data from Mim8 phase 1/2 show that PK/PD profiles support weekly to monthly low volume dosing Mim8 pharmacokinetic properties support Higher potency of Mim8 vs emicizumab weekly and monthly dosing enabling a low dosing volume
Slide 78: Mim8 safety and exploratory efficacy
78 Investor presentation First three months of 2023 Novo Nordisk® In the phase 1/2 trial, Mim8 appeared to have a well tolerated safety profile and read out with exploratory efficacy Low number of patients with treated bleeds after cohort 1 Mim8 safety characteristics Adverse events 10 Patients with
Slide 79: Pivotal phase 3 trial with Mim8
79 Investor presentation First three months of 2023 Novo Nordisk® The pivotal phase 3 trial with Mim8 was initiated in Q4 2022 Trial design FRONTIER 2: Mim8 phase 3 pivotal trial in ~260 adults & adolescents • Novel and accelerated design minimising time from phase 2 into phase 3. Dosing started in
Slide 80: Norditropin market leader, Sogroya opportunity
80 Investor presentation First three months of 2023 Novo Nordisk® While Norditropin® is the market leader within GHD market, Sogroya® represents an opportunity for patients Novo Nordisk leadership in competitive hGH market A portfolio offering across markets DKK Value billion MS% Sogroya® launches 2
Slide 81: Sogroya phase 3a trial results
81 Investor presentation First three months of 2023 Novo Nordisk® Sogroya® phase 3 trial successfully completed with aspirational target product profile achieved Phase 3a trial results in children with GHD Key highlights Efficacy ETD (95% CI) = -0.5 (-1.1 ; 0.2) • Non-inferiority versus Norditropin®
Slide 82: Partnership with 2seventy bio in genome editing
82 Investor presentation First three months of 2023 Novo Nordisk® Novo Nordisk and 2seventy bio extend partnership in next- generation genome editing for people with haemophilia A Lifelong correction via a unique modality Mode of action Potentially lifelong correction of FVIII deficiency Normal Doub
Slide 83: Other serious chronic diseases
83 Investor presentation First three months of 2023 Other serious chronic diseases The unmet needs 84 Cardiovascular disease 86 Non-alcoholic steatohepatitis 90 Alzheimer’s disease 95 Stem cells 98
Slide 84: Expanding into other serious chronic diseases
84 Investor presentation First three months of 2023 Novo Nordisk® Novo Nordisk is expanding into other serious chronic diseases Serious chronic diseases are associated with diabetes and obesity New therapeutic areas represent patient populations with high unmet medical needs Estimated patients • Pat
Slide 85: Patient overlaps guide focused approach in CVD
85 Investor presentation First three months of 2023 Novo Nordisk® Large patient overlaps between diabetes, obesity, and CVD have guided the focused approach in CVD Population overlap between T2D, obesity and CVD Focused approach in CVD ILLUSTRATIVE Atherosclerosis Heart failure ASCVD + HF ASCVD Hear
Slide 86: Late-stage CVD pipeline
86 Investor presentation First three months of 2023 Novo Nordisk® Innovative late-stage CVD pipeline provides opportunities to make a difference for many patients Focus areas Examples of unmet needs in CVD pipeline Near-term Category Broader indications Stand-alone CVD Leverage broader CV indication
Slide 87: Ziltivekimab phase 2b RESCUE trial
87 Investor presentation First three months of 2023 Novo Nordisk® Ziltivekimab phase 2b RESCUE trial was successfully completed In the RESCUE trial, ziltivekimab QM showed reduction in hsCRP at all dose levels 2 % change1 0% 12 weeks of treatment End of treatment • In the RESCUE trial, Data from zil
Slide 88: ZEUS trial with ziltivekimab
88 Investor presentation First three months of 2023 Novo Nordisk® ZEUS trial with ziltivekimab aims to validate the link between inflammation and major adverse cardiovascular events Phase 3 CVOT trial ZEUS with ziltivekimab Objective • To investigate the cardiovascular benefit of ziltivekimab in the
Slide 89: Ziltivekimab unmet need in over 5 million people
89 Investor presentation First three months of 2023 Novo Nordisk® Ziltivekimab aspires to address an unmet need in more than 5 million people in patients with ASCVD, CKD and inflammation Ziltivekimab aspires to reduce MACE in Sub-header Critical (can be success factors to commercialise removed) zilt
Slide 90: NASH progressive disease with no approved treatment
90 Investor presentation First three months of 2023 Novo Nordisk® NASH is a progressive disease with no approved treatment and low diagnosis rates today NASH-Cirrhosis F4 NASH F3 NASH F3 NASH NASHF2 F2 NASH F1 NASH F1 Dead cell Inflamed/dying remnants hepatocyte Scar Inflamed/dying Excessive collage
Slide 91: NASH patient journey and barriers
91 Investor presentation First three months of 2023 Novo Nordisk® NASH patient journey underscores key barriers to overcome for Novo Nordisk to be successful ~22 million people are expected Hurdles to live with NASH F2-F4c by 2030 Global patients (in millions) 25 Low disease No Inadequate patient No
Slide 92: Support for non-invasive tests for NASH diagnosis
92 Investor presentation First three months of 2023 Novo Nordisk® Novo Nordisk is supporting use of non-invasive tests for NASH diagnosis Development and adoption of non-invasive tests (NITs) Novo Nordisk activities supporting non-invasive tests in NASH diagnosis Real world • Linking biomarkers and
Slide 93: Semaglutide phase 2 NASH resolution
93 Investor presentation First three months of 2023 Novo Nordisk® In phase 2, semaglutide showed significant improvements in NASH resolution Semaglutide showed resolution of NASH with no worsening of Semaglutide showed numerical improvements in fibrosis and fewer fibrosis versus placebo in the phase
Slide 94: ESSENCE phase 3a trial in NASH
94 Investor presentation First three months of 2023 Novo Nordisk® Phase 3a trial ESSENCE with semaglutide 2.4 mg for the treatment of NASH was initiated in Q1 2021 The phase 3a ESSENCE trial in NASH ESSENCE trial | NASH F2–F3 patients Primary objectives and endpoints for Part 1 and 2 N = 1,200 Part
Slide 95: Alzheimer's disease patient journey and barriers
95 Investor presentation First three months of 2023 Novo Nordisk® Alzheimer’s disease patient journey is complex and underscores key barriers to overcome for Novo Nordisk to be successful Significant and growing Hurdles unmet need Million 80 Early symptoms Complex tests and Lack of prognostic Limite
Slide 96: Data supporting semaglutide in Alzheimer's phase 3
96 Investor presentation First three months of 2023 Novo Nordisk® Entering phase 3 development of semaglutide in Alzheimer’s disease was based on a number of data points Real world evidence trials Randomised controlled trials Pre-clinical studies Four RWE studies show reduced risk of 53% lower risk
Slide 97: evoke and evoke+ trials
97 Investor presentation First three months of 2023 Novo Nordisk® evoke and evoke+ trials are ongoing with expected completion in 2025 evoke and evoke+ trials have been initiated with 1,840 patients in each trial with a total of 3,680 patients 3 mg 7 mg 14 mg oral semaglutide QD 14 mg oral semagluti
Slide 98: Potential for cell therapies and Novo Nordisk capabilities
98 Investor presentation First three months of 2023 Novo Nordisk® There is broad potential for cell therapies and Novo Nordisk has capabilities to explore the potential Broad potential for clinical use of cell therapies Maturing the platform to enable development of competitive cell therapies Parkin
Slide 99: Cell therapy collaboration with Heartseed
99 Investor presentation First three months of 2023 Novo Nordisk® Potential first human dose with cell therapy in collaboration with Heartseed and others Utilise internal capabilities and disease understanding Accelerate innovation through partnerships for stem cell development Internal capabilities
Slide 100: Cell therapies in heart failure and Parkinson's trials
100 Investor presentation First three months of 2023 Novo Nordisk® First efforts to combine Novo Nordisk and partner competencies in cell therapies start with heart failure and Parkinson’s disease TRANSCEND 1 and 2 trials to evaluate stem cells impact on Heartseed: Phase 1/2 trial in patients with s
Slide 101: International Operations
Novo Nordisk® 101 101 101 Investor presentation First three months of 2023 International Operations IO at a glanceOperations International 107 102 EMEA 112 108 Region China 117 113 Rest of World 122 118
Slide 102: Growth momentum driven by demographics and full portfolio
102 Investor presentation First three months of 2023 Novo Nordisk® Growth momentum has increased driven by demographics and utilisation of full product portfolio Historic growth has been in the Growth momentum in IO International Operations is diverse and covers 190 markets range of 5-10% >487m 16%
Slide 103: International Operations at a glance
103 Investor presentation First three months of 2023 Novo Nordisk® International Operations at a glance Diabetes trend Diabetes market by value and Novo Novo Nordisk reported sales Million DKK Nordisk market share billion First quarter of Sales 19% Growth2 2023 (mDKK) 17% Total GLP-13 8,833 52% 600
Slide 104: Diabetes market share and growth in International Operations
104 Investor presentation First three months of 2023 Novo Nordisk® Diabetes market share and market growth in International Operations Diabetes market growth and Novo Nordisk market share Diabetes market size and growth DKK billion 160% 40% ~13% 7 217 8 9 192 120% 30% 80% 18% 20% 13% 40% 36% 10% ~18
Slide 105: GLP-1 market share and market growth
105 Investor presentation First three months of 2023 Novo Nordisk® GLP-1 market share and market growth GLP-1 market growth and Novo Nordisk market share GLP-1 market size and growth DKK billion 100% 80% ~46% 3 41 10 80% 76% 0 60% 58% 28 60% 65% 46% 40% 40% ~58% 61% 65% 20% 60% 20% 56% 60% 55% 0% 0%
Slide 106: Insulin market in International Operations
106 Investor presentation First three months of 2023 Novo Nordisk® Insulin market size and volume share of growth and market share in International Operations Insulin market share and market size (DKK billion) Market Δ Market Insulin volume: Market share growth share -4.3% +0.8% 80% 10% Total 51% 60
Slide 107: Obesity market in International Operations
107 Investor presentation First three months of 2023 Novo Nordisk® Obesity market share and market growth in International Operations Obesity market growth and Novo Nordisk market share Obesity market size and growth DKK billion ~50% 0.2 6.4 90% 86% 90% 2.0 70% 67% 60% 4.3 50% 50% 30% 30% 67% ~86% 0
Slide 108: EMEA at a glance
EMEA 108 Investor presentation First three months of 2023 Novo Nordisk® EMEA at a glance Diabetes trend Diabetes market by value and Novo Novo Nordisk reported sales Nordisk market share Million DKK First quarter of Sales billion Growth2 2023 (mDKK) 300 25% Total GLP-13 5,048 57% 150 100% 19% Long-a
Slide 109: Diabetes market in EMEA
EMEA 109 Investor presentation First three months of 2023 Novo Nordisk® Diabetes market share and market growth in EMEA Diabetes market growth and Novo Nordisk market share DKK Diabetes market size and growth billion 75% 20% ~17% 17% 6 119 6 5 102 17% 15% 50% 10% 30% 25% 29% 5% ~17% 29% 29% 0% 0% Fe
Slide 110: GLP-1 market in EMEA
EMEA 110 Investor presentation First three months of 2023 Novo Nordisk® GLP-1 market share and market growth in EMEA GLP-1 market growth and Novo Nordisk market share GLP-1 market size and growth DKK billion 80% 80% ~38% 3 27 67% 5 0 61% 60% 60% 19 43% 40% 38% 40% ~43% 59% 20% 20% 61% 56% 57% 59% 0%
Slide 111: Insulin market in EMEA
EMEA 111 Investor presentation First three months of 2023 Novo Nordisk® Insulin market size and volume market share in EMEA Insulin market share and market size (DKK billion) Market Δ Market Insulin volume: Market share growth share 60% 10% Total 48% 49% 37 1.2% -0.1% 47% 7% Long- 40% 41% 20 3.8% +1
Slide 112: Obesity market in EMEA
EMEA 112 Investor presentation First three months of 2023 Novo Nordisk® Obesity market share and market growth in EMEA Obesity market growth and Novo Nordisk market share DKK Obesity market size and growth billion ~85% 120% 120% 2.8 109% 0.1 100% 100% 84% 1.2 80% 80% 85% 1.5 60% 60% ~109% 84% 40% 40
Slide 113: Region China at a glance
Region China 113 Investor presentation First three months of 2023 Novo Nordisk® Region China at a glance Diabetes trend Diabetes market by value and Novo Novo Nordisk reported sales Nordisk market share Million DKK First quarter of Sales billion Growth2 2023 (mDKK) 200 6% Total GLP-13 1,349 56% 14%
Slide 114: Diabetes market in Region China
Region China 114 Investor presentation First three months of 2023 Novo Nordisk® Diabetes market share and market growth in Region China Diabetes market growth and Novo Nordisk market share DKK Diabetes market size and growth billion 50% 40% ~-2% 27 1 26 40% 30% 0 -1 32% 30% 20% 20% 10% -2% ~-5% 32%
Slide 115: GLP-1 market in Region China
Region China 115 Investor presentation First three months of 2023 Novo Nordisk® GLP-1 market share and market growth in Region China GLP-1 market growth and Novo Nordisk market share GLP-1 market size and growth DKK billion 160% 160% ~102% 1 0 4 120% 120% 1 103% 102% 80% 80% 67% 2 67% ~103% 66.9% 67
Slide 116: Insulin market in Region China
Region China 116 Investor presentation First three months of 2023 Novo Nordisk® Insulin market size and volume share of growth and market share in Region China Insulin market share and market size (DKK billion) Market Δ Market Insulin volume: market share growth share 80% 50% Total 53% 11 -26.1% +2.
Slide 117: Region China remains a key strategic opportunity
Region China 117 Investor presentation First three months of 2023 Novo Nordisk® Region China remains a key strategic opportunity Region China is a large market with Outcome of VBP insulin in China Opportunities and strategic priorities ~140 million people living with diabetes Large growing diabetes
Slide 118: Rest of World at a glance
Rest of World 118 Investor presentation First three months of 2023 Novo Nordisk® Rest of World at a glance Diabetes trend in population Diabetes market by value and Novo Nordisk reported sales Novo Nordisk market share Million DKK First quarter of Sales Growth2 2023 (mDKK) 21% billion 300 Total GLP-
Slide 119: Diabetes market in Rest of World
Rest of World 119 Investor presentation First three months of 2023 Novo Nordisk® Diabetes market share and market growth in Rest of World Diabetes market growth and Novo Nordisk market share DKK Diabetes market size and growth billion 25% 55% ~12% 20% 2 71 45% 4 2 20% 64 35% 38% 15% 25% 10% 12% 15%
Slide 120: GLP-1 market in Rest of World
Rest of World 120 Investor presentation First three months of 2023 Novo Nordisk® GLP-1 market share and market growth in Rest of World GLP-1 market growth and Novo Nordisk market share DKK GLP-1 market size and growth billion 110% 160% 102% ~52% 3 10 90% 0 0 120% 76% 70% 86% 7 80% 50% 52% 76% 40% ~8
Slide 121: Insulin market in Rest of World
Rest of World 121 Investor presentation First three months of 2023 Novo Nordisk® Insulin market size and volume market share in Rest of World Insulin market share and market size (DKK billion) Market Δ Market Insulin volume: Market share growth share 80% 20% Total 58% 12 6.3% +1.1% 15% 42% 60% 58% L
Slide 122: Obesity market in Rest of World
Rest of World 122 Investor presentation First three months of 2023 Novo Nordisk® Obesity market share and market growth in Rest of World Obesity market growth and Novo Nordisk market share Obesity market size and growth DKK billion 70% 40% ~31% 65% 3.6 0.1 60% 31% 30% 0.8 50% 2.8 54% 20% 40% 30% 10%
Slide 123: North America Operations
123 Investor presentation First three months of 2023 Novo Nordisk® North America Operations NAO growth drivers 128 USA health care system 125 USA health care system 129 NAO at a glance 126 NAO at a glance 131
Slide 124: North America Operations growth has accelerated
NAO 124 Investor presentation First three months of 2023 Novo Nordisk® North America Operations growth has accelerated North America Operations reported sales growth per therapy area DKK billion 1% 3% 14% 21% 41% 100 91 80 67 60 61 60 40 29 20 0 2019 2020 2021 2022 Q1 2023 GLP-1 Insulin Other diabet
Slide 125: US health insurance dominated by a few large payers
NAO 125 Investor presentation First three months of 2023 Novo Nordisk® US health insurance is dominated by a few large commercial payers US population by health insurance status Development of Novo Nordisk rebates Covered lives by PBM has been stable in recent years DKK and net sales in the US billi
Slide 126: North America Operations at a glance
NAO 126 Investor presentation First three months of 2023 Novo Nordisk® North America Operations at a glance Diabetes trend in population Diabetes market by value and Novo Nordisk reported sales Novo Nordisk market share Million DKK First quarter of Sales Growth2 billion 2023 (mDKK) 70 10% Total GLP-
Slide 127: Diabetes market in North America Operations
NAO 127 Investor presentation First three months of 2023 Novo Nordisk® Diabetes market share and market growth in North America Operations Diabetes market growth and Novo Nordisk market share Diabetes market size and growth DKK 50% billion ~35% 58 753 41% 63 38% 40% 75 35% 558 34% 30% 20% 10% ~41% 3
Slide 128: GLP-1 market in North America Operations
NAO 128 Investor presentation First three months of 2023 Novo Nordisk® GLP-1 market share and market growth in North America Operations GLP-1 market growth and Novo Nordisk market share GLP-1 market size and growth DKK billion 70% 80% ~71% 60 309 72% -1 69 60% 71% 54% 60% 181 50% 53% ~72% 40% 40% 54
Slide 129: Total Rybelsus TRx volume growing in the US
NAO 129 Investor presentation First three months of 2023 Novo Nordisk® Total Rybelsus® TRx volume is steadily growing in the US Rybelsus® and SGLT-2i1 uptake in the US2 since respective launches In the first three months of 2023, Rybelsus® sales account for 14% share of growth of NAO sales TRx count
Slide 130: Volume market shares in three insulin segments
NAO 130 Investor presentation First three months of 2023 Novo Nordisk® Novo Nordisk volume market shares in the three insulin segments Long-acting insulin Premix insulin Fast-acting insulin tMU MS tMU MS tMU MS 100 80% 80 80% 80 100% CAGR volume1: -0.8% CAGR volume1: -7.9% CAGR volume1: 1.4% MI pene
Slide 131: Insulin market in North America Operations
NAO 131 Investor presentation First three months of 2023 Novo Nordisk® Insulin market size and volume market share in North America Operations Insulin market share and market size (DKK billion) Market Δ Market Insulin volume: Market share growth share 60% 12% Total 43% 214 5.8% +0.6% 8% Long- 40% 38
Slide 132: Obesity market in North America Operations
NAO 132 Investor presentation First three months of 2023 Novo Nordisk® Obesity market share and market growth in North America Operations Obesity market growth and Novo Nordisk market share Obesity market size and growth DKK 100% 95% 220% billion ~88% 23.3 180% 0.1 80% 140% 10.8 60% 96% 100% 12.4 40
Slide 133: Financials
133 133 133 Investor presentation First three months of 2023 Novo Nordisk® Financials Profit and loss, capital allocation 139 134 Currencies 145 140
Slide 134: Solid sales growth driven by Diabetes and Obesity care
134 Investor presentation First three months of 2023 Novo Nordisk® Solid sales growth driven by Diabetes and Obesity care Reported annual sales 2018-2022 Expected development towards 2025 DKK billion Gross margin Remain broadly stable 12% +12%1 14% Gradually decline enabled by S&D cost ratio attract
Slide 135: Solid operating profit growth driven by Diabetes care
135 Investor presentation First three months of 2023 Novo Nordisk® Solid operating profit growth driven by Diabetes care Operating profit Operating profit split by franchise DKK -4% 11% 3% 8% 28% Percent billion of sales 3% 6% 7% 13% 15% 80 60% 10% 20% 60 40% 40 80% 90% 20% 20 0 0% 2018 2019 2020 20
Slide 136: Resource allocation guided by investing in future growth
136 Investor presentation First three months of 2023 Novo Nordisk® Resource allocation in Novo Nordisk is guided by investing in future growth while delivering attractive shareholder returns Corporate strategy guides resource allocation Expected primary sales growth drivers towards 2030 ILLUSTRATIVE
Slide 137: Net profit converted to cash and returned to shareholders
137 Investor presentation First three months of 2023 Novo Nordisk® Net profit has been converted to cash and returned to shareholders Cash conversion and allocation (2022) Strategic capital allocation priorities DKK billion Business development investments to enhance R&D pipeline 70 CAPEX investment
Slide 138: Rare disease segment has lower profitability
138 Investor presentation First three months of 2023 Novo Nordisk® Rare disease segment has lower profitability driven by higher investments in R&D including the acquisition of Forma in 2022 Diabetes and Obesity care P&L – full year 2022 Rare disease P&L – full year 2022 DKK DKK billion billion 200
Slide 139: Step-up in CAPEX to meet demand
139 Investor presentation First three months of 2023 Novo Nordisk® Step-up in CAPEX to meet demand for current and future products CAPEX investments Ensure readiness to meet future demands DKK billion 30 ~25 24 9% 7% 7% 7% 18 • Capital expenditure is expected to be around DKK 25 5% 4% billion in 202
Slide 140: Currency impact on Novo Nordisk's P/L
140 Investor presentation First three months of 2023 Novo Nordisk® Currency impact on Novo Nordisk’s P/L Operational currency impact Financial currency impact • All movements in currencies will directly impact the • All gain/losses from hedging contracts are included in individual reported functiona
Slide 141: Attractive capital allocation to shareholders
141 Investor presentation First three months of 2023 Novo Nordisk® Attractive capital allocation to shareholders Annual cash return to shareholders Capital allocation DKK billion 60 • The proposed final dividend of 8.15 DKK per share, in addition to the interim dividend of 4.25 DKK per share, corres
Slide 142: Operating profit impacted by currencies in 2023
142 Investor presentation First three months of 2023 Novo Nordisk® Operating profit expected to be negatively impacted by currencies in 2023, partly countered by net financials Avg. FY 2022 vs. Avg. FY 2021 Exp. Avg FY 2023 1vs. FY 2022 20% FY 2022 • Positive impact on operating profit of DKK 7.6 10
Slide 143: Purpose & Sustainability
143 Investor presentation First three months of 2023 Novo Nordisk® Purpose & Sustainability Sustainable business 148 144 Environmental responsibility 150 147 Social responsibility 153 149 Governance 158 154 RANJITH S. Ranjith lives with type 1 diabetes India
Slide 144: Long-term value to society driven by purpose
144 Investor presentation First three months of 2023 Novo Nordisk® Long-term value to society is driven by a strong sense of purpose and by being a responsible business Foundation ownership enables long-term focus on ESG1 responsibility has been anchored in shared value creation Articles of Associat
Slide 145: 2022 statement of ESG performance
145 Investor presentation First three months of 2023 Novo Nordisk® 2022 statement of ESG performance 2022 2021 2020 Resources Energy consumption for operations (1,000 GJ) 3,677 3,387 3,191 Share of renewable power for production sites 100% 100% 100% Water consumption for production sites (1,000 m3)
Slide 146: Circular for Zero environmental aspiration
146 146 Investor presentation First three months of 2023 Novo Nordisk® With Circular for Zero, Novo Nordisk aspires to have zero environmental impact Environmental aspirations Circular products Upgrade existing and design new products based on circular principles and solve the end-of-life product wa
Slide 147: Net-zero emissions pledge by 2045
147 Investor presentation First three months of 2023 Novo Nordisk® Novo Nordisk pledges to reach net-zero emissions across the entire value chain by 2045 Emissions from Scope 1, 2 and 31 Key initiatives to reduce CO2 emissions across all three scopes 1,000 tonnes CO2 Scope 11 - Direct emissions from
Slide 148: Plastic footprint challenge
148 Investor presentation First three months of 2023 Novo Nordisk® Reaching more patients will increase the plastic footprint, a challenge Novo Nordisk has started to address Growing volumes impact Novo Nordisk’s plastic footprint Change to sustainable plastic ILLUSTRATIVE • Engage with suppliers to
Slide 149: Social responsibility: prevention, access and innovation
149 Investor presentation First three months of 2023 Novo Nordisk® Social responsibility is core to Novo Nordisk and initiatives focus on prevention, access and innovation …accelerating …providing access to …innovating to prevention to affordable care for vulnerable improve lives… bend the curve… pa
Slide 150: More than 5 million people reached with access initiatives
150 Investor presentation First three months of 2023 Novo Nordisk® In 2022, more than 5 million people with diabetes were reached with access and affordability initiatives 5.5 out of 36.3 million people were reached A number of focused programmes (as of full year 2022) with access and affordability
Slide 151: US net prices have declined in last five years
151 Investor presentation First three months of 2023 Novo Nordisk® In the US, net prices have declined in the last five years The US population by health insurance Net prices1 across the full Novo coverage Insulin net prices1 have declined Nordisk portfolio2 declined 150 150 7% 120 120 106 100 101 1
Slide 152: Barriers to access go beyond price
152 Investor presentation First three months of 2023 Novo Nordisk® Barriers to access go beyond price Diabetes Compass launched with Thermal solution for human insulin can iCare initiative towards strengthening World Diabetes Foundation address one key access to care barrier health infrastructure in
Slide 153: Sustainable employer: inclusive and diverse
153 Investor presentation First three months of 2023 Novo Nordisk® The journey towards being a sustainable employer starts with being inclusive and diverse 2025 aspiration supporting Diversity and Inclusion Driving an inclusive and diverse workplace Diversity & Inclusion aspirational targets: • Crea
Slide 154: Corporate governance structure
154 Investor presentation First three months of 2023 Novo Nordisk® Structure in place to ensure corporate governance Rules and Regulations Governance structure Assurance measures Shareholders A and B share structure Danish and foreign laws and Audit financial data and review regulations social and e
Slide 155: Sustainable tax approach
155 Investor presentation First three months of 2023 Novo Nordisk® Novo Nordisk has a sustainable tax approach Sustainable tax approach approved by the BoD Corporate income taxes by region – three year average in DKK billion 1 | Commercially driven Corporate Region IP rights1 Production2 Sales3 inco
Slide 156: ESG integrated in reporting and remuneration
156 Investor presentation First three months of 2023 Novo Nordisk® ESG is integrated in reporting and remuneration as well as recognised externally ESG is included in integrated reporting and We strive to adhere to sustainability ESG rankings by third-party agencies short- and long-term remuneration
Slide 157: Investor contact information
157 Investor presentation First three months of 2023 Novo Nordisk® Investor contact information Share information Investor Relations contacts Novo Nordisk’s B shares are listed on the stock exchange in Novo Nordisk A/S Copenhagen under the symbol ‘NOVO B’. Its ADRs are listed on the Investor Relatio